Corlanor FDA Approval History
FDA Approved: Yes (First approved April 15, 2015)
Brand name: Corlanor
Generic name: ivabradine
Dosage form: Tablets and Oral Solution
Company: Amgen Inc.
Treatment for: Heart Failure
Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated for the treatment of chronic heart failure.
Development timeline for Corlanor
| Date | Article |
|---|---|
| Apr 15, 2015 | Approval FDA Approves Corlanor (ivabradine) to Treat Heart Failure |
| Aug 27, 2014 | FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
